Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms

Chest

Volumn 128, Issue 3, 2005, Pages 1128-1135

  Littner, Michael R ^a,d   Leung, Felix W ^a   Ballard II, E David ^b   Huang, Bidan ^c   Samra, Nina K ^b  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b TAP PHARMACEUTICAL PRODUCTS INC   (United States)

^c ABBOTT LABORATORIES   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Asthma; Exacerbation; Gastroesophageal acid reflux; Lansoprazole; Proton pump inhibitor

Indexed keywords

ANTACID AGENT; ATTAPULGITE; CORTICOSTEROID; LANSOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; SALBUTAMOL;

ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EMOTION; FEMALE; FORCED EXPIRATORY VOLUME; GASTROESOPHAGEAL REFLUX; HUMAN; INFECTION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYMPTOM; UNITED STATES;

EID: 24944511128     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.3.1128     Document Type: Article

References (23)

1. Gibson PG, Henry RL, Coughlan JL. Gastro-esophageal reflux treatment for asthma in adults and children. Cochrane Database Syst Rev (database online). Issue 2, 2002
2. Sontag SJ, O'Connell S, Khandelwal S, et al. Asthmatics with gastroesophageal reflux: long term results of a randomized trial of medical and surgical antireflux therapies. Am J Gastroenterol 2003; 98:987-999
3. Jumper EF, Buist S, Cox FM. et al. Validation of a standardized version of the asthma quality of life questionnaire. Chest 1999; 115:1265-1270
4. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease: the Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1999; 94:1434-1442
5. National Asthma Education and Prevention Program. Expert panel report II: guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, April 1997; NIH Publication No. 97-4051
6. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123:659-664
7. Ayres JG, Campbell LM. A controlled assessment of an asthma self-management plan involving a budesonide dose regimen: OPTIONS Research Group. Eur Respir J 1996; 9:886-892
8. Robinson DS, Campbell D, Barnes PJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet 2001; 357:2007-2011
9. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma: Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337:1405-1411
10. Harding SM, Richter JE, Guzzo MR, et al. Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome. Am J Med 1996; 100:395-405
11. Rinffal N, Cuchalin A, Chovan L, et al. Evaluation of different inhaled combination therapies (EDICT): a randomised, double-blind comparison of Seretide TM (50/250 μg bd Diskus vs. formoterol (12 μg bd) and budesonide (800 μg bd) given concurrently (both via Turbuhaler) in patients with moderate-to-severe asthma. Respir Med 2002; 96:851-861
12. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254-261
13. National Institutes of Health. Global initiative for asthma. Bethesda, MD: National Institutes of Health; NIH Publication No 02-3659, 2002
14. Shrewsbury, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000; 320:1368-1373
15. Pauwels RA. Similarities and differences in asthma and chronic obstructive pulmonary disease exacerbations. Proc Am Thorac Soc 2004; 1:73-79
16. Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994; 47:81-87
17. Levin TR, Sperling RM, McQuaid KR. Omeprazole improves peak expiratory flow rate and quality of life in asthmatics with gastroesophageal reflux. Am J Gastroenterol 1998; 93:1060-1063
18. Harding SM, Guzzo MR, Richter JE. 24-hour pH testing in asthmatics: Respiratory symptom correlation with esophageal acid events. Chest 1999; 115:654-659
19. Kiljander TO, Salomaa E-RM, Hietanen EK, et al. Gastroesophageal reflux in asthmatics: a double-blind, placebo-controlled crossover study with omeprazole. Chest 1999; 116:1257-1264
20. O'Connor JFB, Singer ME, Richter JE. The cost-effectiveness of strategies to assess gastroesophageal reflux as an exacerbating factor in asthma. Am J Gastroenterol 1999; 94:1472-1480
21. Larrain A, Carrasco E, Galleguillos F, et al. Medical and surgical treatment of nonallergic asthma associated with gastroesophageal reflux. Chest 1991; 99:1330-1335
22. Frazzoni M, De Micheli E, Grisendi A, et al. Effective intra-oesophageal acid suppression in patients with gastrooesophageal reflux disease: lansoprazole vs. pantoprazole. Aliment Pharmacol Ther 2003; 17:235-241
23. Timmer W, Ripke H, Kleist P, et al. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy patients. Methods Find Exp Clin Pharmacol 1995; 17:489-495